Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds

The Guardian - World NewsEN 3 min read 100% complete by Anna Bawden Health and social affairs correspondentMarch 10, 2026 at 11:30 PM
Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds

AI Summary

medium article 3 min

A recent study published in the British Journal of Ophthalmology found that Wegovy users have a significantly higher risk of sudden vision loss compared to Ozempic users. The study, which analyzed reports submitted to the FDA between 2017 and 2024, revealed that Wegovy patients had a fivefold greater chance of developing non-arteritic anterior ischemic optic neuropathy (NAION), an "eye stroke" causing permanent vision loss. Researchers compared reports of NAION associated with Wegovy, Ozempic, Rybelsus, and Mounjaro. While Wegovy showed a strong association with vision loss, no increased risk was found with Rybelsus or Mounjaro. The higher dosage and faster-acting injection of Wegovy were cited as potential reasons for the increased risk. All drugs contain GLP-1 RAs, which help reduce blood sugar levels, slow digestion and reduce appetite.

Keywords

wegovy 100% sudden sight loss 90% ozempic 80% semaglutide 70% glp-1 ra 70% naion 70% weight loss 60% vision loss 60% drug safety 50% side effects 50%

Sentiment Analysis

Very Negative
Score: -0.60

Source Transparency

Source
The Guardian - World News
Classification Confidence
90%
Geographic Perspective
United States

This article was automatically classified using rule-based analysis.

Topic Connections

Explore how the topics in this article connect to other news stories

Network visualization showing 2 related topics
View Full Graph
Explore Full Topic Graph

Find Similar Articles

AI-Powered

Discover articles with similar content using semantic similarity analysis.